Clinical TrialAug 12, 2026, 04:23 PM
Atea Pharma's C-BEYOND Phase 3 HCV Trial Meets Endpoints; Q2 Net Loss $(32.9)M
AI Summary
Atea Pharmaceuticals announced positive topline results from its Phase 3 C-BEYOND trial for chronic Hepatitis C virus (HCV), where the BEM/RZR regimen met primary and secondary endpoints, demonstrating non-inferiority to Epclusa®. The company plans to submit a New Drug Application (NDA) in Q2 2027 following expected C-FORWARD trial results in early Q1 2027. For Q2 2026, Atea reported a net loss of $(32.9) million, an improvement from $(37.2) million in Q2 2025, with R&D expenses decreasing to $28.2 million.
Key Highlights
- C-BEYOND Phase 3 trial for HCV met primary and secondary endpoints, showing non-inferiority.
- BEM/RZR regimen achieved 93.9% SVR rate vs. 94.8% for SOF/VEL in mITT analysis.
- NDA submission for BEM/RZR anticipated in Q2 2027 after C-FORWARD results.
- AT-587 Phase 1 clinical trial for Hepatitis E Virus (HEV) is advancing.
- Q2 2026 net loss was $(32.9) million, improved from $(37.2) million YoY.
- R&D expenses decreased to $28.2 million in Q2 2026 from $32.3 million YoY.
- Cash and investments totaled $219.5 million as of June 30, 2026.
Price Impact
More from AVIR